CN104736157B - 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 - Google Patents

抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 Download PDF

Info

Publication number
CN104736157B
CN104736157B CN201380024370.2A CN201380024370A CN104736157B CN 104736157 B CN104736157 B CN 104736157B CN 201380024370 A CN201380024370 A CN 201380024370A CN 104736157 B CN104736157 B CN 104736157B
Authority
CN
China
Prior art keywords
cell
mangiferin
sea
acetyl
mcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380024370.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104736157A (zh
Inventor
梁纯
姜志宏
王紫壹
禹志领
王静蓉
白丽萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University HKBU, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Priority to CN201910489605.4A priority Critical patent/CN110412285B/zh
Publication of CN104736157A publication Critical patent/CN104736157A/zh
Application granted granted Critical
Publication of CN104736157B publication Critical patent/CN104736157B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
CN201380024370.2A 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用 Active CN104736157B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910489605.4A CN110412285B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
PCT/US2013/040287 WO2013169989A1 (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910489605.4A Division CN110412285B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Publications (2)

Publication Number Publication Date
CN104736157A CN104736157A (zh) 2015-06-24
CN104736157B true CN104736157B (zh) 2019-06-11

Family

ID=49551267

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380024370.2A Active CN104736157B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用
CN201910489605.4A Active CN110412285B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910489605.4A Active CN110412285B (zh) 2012-05-09 2013-05-09 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用

Country Status (9)

Country Link
US (1) US11648258B2 (https=)
EP (2) EP2846807B1 (https=)
JP (6) JP2015517500A (https=)
CN (2) CN104736157B (https=)
AU (1) AU2013259486B2 (https=)
CA (2) CA2873283C (https=)
ES (1) ES2949335T3 (https=)
IN (1) IN2014MN02513A (https=)
WO (1) WO2013169989A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948119B (zh) * 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
DE10248751A1 (de) 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
EP1755649A1 (en) * 2004-04-14 2007-02-28 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
EP1833991A4 (en) 2004-12-22 2011-11-16 Auckland Uniservices Ltd TREFOIL FACTORS AND METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES THEREWITH
EP1787645A1 (en) 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
WO2010068247A1 (en) 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer;Gouji Toyokawa et al.;《Molecular Cancer》;20111231;第10卷(第1期) *
海杧果属红树植物的化学成分及其生物活性研究概述;徐艳等;《广西科学院学报》;20110228;第27卷(第01期);55-61 *

Also Published As

Publication number Publication date
EP2846807A4 (en) 2016-07-27
EP4248978A3 (en) 2023-11-08
JP2015517500A (ja) 2015-06-22
EP2846807A1 (en) 2015-03-18
CN110412285B (zh) 2022-11-15
CA2873283A1 (en) 2013-11-14
JP2018100274A (ja) 2018-06-28
JP2020073544A (ja) 2020-05-14
US11648258B2 (en) 2023-05-16
CN110412285A (zh) 2019-11-05
CA2873283C (en) 2021-05-04
JP2025169320A (ja) 2025-11-12
WO2013169989A1 (en) 2013-11-14
JP2021193132A (ja) 2021-12-23
CN104736157A (zh) 2015-06-24
CA3111702A1 (en) 2013-11-14
AU2013259486B2 (en) 2019-12-12
IN2014MN02513A (https=) 2015-07-17
AU2013259486A1 (en) 2014-12-18
EP2846807B1 (en) 2023-06-07
EP4248978A2 (en) 2023-09-27
CA3111702C (en) 2025-03-18
US20150099712A1 (en) 2015-04-09
ES2949335T3 (es) 2023-09-27
EP2846807C0 (en) 2023-06-07
JP2024001049A (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
Xu et al. Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma
Kim et al. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial–mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance
Zhao et al. Potent effects of dioscin against gastric cancer in vitro and in vivo
Gu et al. Icariin exerts inhibitory effects on the growth and metastasis of KYSE70 human esophageal carcinoma cells via PI3K/AKT and STAT3 pathways
He et al. Liquiritin (LT) exhibits suppressive effects against the growth of human cervical cancer cells through activating Caspase-3 in vitro and xenograft mice in vivo
CN104736157B (zh) 抑制mcm蛋白复合物的方法和化合物及其在治疗癌症上的应用
Li et al. The effect of dihydroartemisinin on the malignancy and epithelial-mesenchymal transition of gastric cancer cells
Zhu et al. LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1
Zhu et al. Cycloastragenol induces apoptosis and protective autophagy through AMPK/ULK1/mTOR axis in human non-small cell lung cancer cell lines
Byun et al. C-27-carboxylated oleanane triterpenoids up-regulate TRAIL DISC assembly via p38 MAPK and CHOP-mediated DR5 expression in human glioblastoma cells
Shan et al. Inonotsutriol E from Inonotus obliquus exhibits promising anti breast cancer activity via regulating the JAK2/STAT3 signaling pathway
Wang et al. Liquiritigenin inhibits the migration, invasion, and EMT of prostate cancer through activating ER stress
Dai et al. Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins
Tan et al. Gypensapogenin H suppresses tumor growth and cell migration in triple-negative breast cancer by regulating PI3K/AKT/NF-κB/MMP-9 signaling pathway
Xue et al. A novel protoapigenone analog RY10-4 induces apoptosis of breast cancer cells by exacerbating mitochondrial Ca2+ influx through mitochondrial calcium uniporter
Liu et al. Corilagin induces laryngeal cancer antiproliferation and inhibits growth factor and cytokine signaling pathways in vitro and in vivo
US20240382509A1 (en) Cannabinoids C- and O-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof
Huang et al. Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription
US20230293564A1 (en) Method and compounds for inhibiting the MCM complex and their application in cancer treatment
HK40016841B (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
HK40016841A (en) Method and compounds for inhibiting the mcm protein complex and their application in cancer treatment
CN114053285A (zh) 灵芝酸x在治疗肿瘤中的应用
CN112358527A (zh) 丙烯酸雷公藤甲素酯、其制备方法及其应用
HK40100635A (en) Method and compounds for inhibiting the mcm complex and their application in cancer treatment
KR20210017823A (ko) 골수성 백혈병의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant